Novel Preclinical Models in Oncology

Selection of appropriate animal models based on similarity to human biology carries considerable potential to ensure a higher predictability of preclinical trials.

Cambridge Healthtech Institute’s Novel Preclinical Models in Oncology conference aims to bring together cancer researchers and clinicians in order to initiate knowledge and opinion exchange around preclinical models and their optimization. Highly characterized patient-derived tumor tissue xenograft models that allow us to more effectively evaluate novel targeted therapeutics as well as to identify predictive biomarkers in early stages of drug development will be discussed along with other novel models of cancer. Case studies and solutions for increasing the predictability of preclinical cancer studies will be presented.

Preliminary Agenda

PDX MODELS NEW STRATEGIES

Statistical Analysis of PDX Studies and Preclinical Phase-II-Like Trials (PP2T) at EMD Serono

Anderson Clark, Ph.D., Director, In vivo Pharmacology, Oncology, EMD Serono Research & Development Institute

Preclinical Models for Precision Medicine in Metastatic Colorectal Cancer: Challenges and Opportunities

Livio Trusolino, M.D., Ph.D., Associate Professor, Department of Oncological Sciences, University of Torino School of Medicine, Laboratory of Molecular Pharmacology, IRCC, Institute for Cancer Research and Treatment

Dual Wnt and EGFR-MAPK dependency of BRAFV600E-Mutant Colorectal Cancer

Youzhen Wang, Ph.D., Principal Scientist, Novartis Institutes for BioMedical Research 

Efficient Preclinical Modeling of Combinations
Arijit Chakravarty, Ph.D., Director, Modeling & Simulation (DMPK), Takeda Pharmaceutical International Co.

MODELING TUMOR GENOMIC HETEROGENEITY

Modeling Tumor Dormancy and Recurrence

Jeffrey E. Green, M.D., Chief, Transgenic Oncogenesis and Genomics Section, Laboratory of Cancer Biology and Genetics, National Cancer Institute

Developing and Deploying Novel Experimental Model Systems in Ovarian Cancer for Improved Drug Discovery

Ronny I. Drapkin, M.D., Ph.D., Assistant Professor, Department of Pathology, Harvard Medical School

Zebrafish as a Model for Cancer Research: Studying Tumor Genomic Heterogeneity

Presenter to be Announced, Laboratory of Leonard I. Zon, M.D., Grousbeck Professor of Pediatric Medicine, Harvard Medical School; Investigator, Howard Hughes Medical Institute; Director, Stem Cell Program, Children’s Hospital Boston

IMAGING ADVANCES AND END POINTS IN CANCER RESEARCH

Translational Imaging in Oncology

Daniel P. Bradley, Ph.D., Head, Biomedical Imaging at Takeda Boston, Takeda Pharmaceuticals International Co.

Accelerating Preclinical Drug Development by in vivo and ex vivo Imaging in Cancer Models: Optimizing Discovery to Delivery

Werner Scheuer, Research Leader, Pharma Research and Early Development, Discovery Oncology, Roche Diagnostics GmbH

Normalizing Tumor Microvasculature And Microenvironment

Dai Fukumura, M.D., Ph.D., Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital & Harvard Medical School

For questions about the meeting, please contact:
Marina Filshtinsky, M.D.
Senior Director, Conferences
Cambridge Healthtech Institute
T: (+1) 973-525-4667
E: mfilshtinsky@healthtech.com

For sponsorship and exhibit information, contact:
Joseph Vacca
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: jvacca@healthtech.com